GoodRx Holdings (GDRX) AI Stock Analysis

• Market Cap: $634.74M
• Dividend Yield: N/A
• Average Volume (3M): 3.03M
• Price to Earnings (P/E): 22.2
• Beta (1Y): 0.80
• Revenue Growth: 1.30%
• EPS Growth: N/A
• Country: US
• Employees: 738
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.09
• Shares Outstanding: 105,468,834
• 10 Day Avg. Volume: 2,220,720
• 30 Day Avg. Volume: 3,029,798
• PEG Ratio: 0.12
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 1.21
• P/FCF Ratio: 12.57
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 0.54
• Enterprise Value/Gross Profit: 0.59
• Enterprise Value/Ebitda: 2.38
• 1Y Price Target: $3.32
• Price Target Upside: 77.54% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12
• EPS Forecast (FY): 0.35
• Revenue Forecast (FY): $776.93M

• Rating: 60 Neutral
• Price Target: $2.00 ▲(6.95% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score reflects improving financial quality (stronger balance sheet and positive cash generation) but is held back by weak technical momentum and management guidance pointing to lower 2026 revenue and EBITDA amid continued pressure in the legacy prescription transactions business. Valuation is not low enough (P/E ~28.5) to fully offset these near-term growth risks, despite encouraging growth in Pharma Direct.

Positive Factors

De-risked balance sheet

Material debt reduction and a larger equity base in 2025 materially lower refinancing and solvency risk. A healthier balance sheet preserves financial optionality to fund strategic investments, absorb partner shocks, and maintain capital returns, supporting multi-quarter resilience.

Consistent cash generation

Sustained operating and free cash flow provide a durable funding source for reinvestment in growth (Pharma Direct, subscriptions), opportunistic buybacks, and working capital, reducing dependence on external financing and enabling multi-quarter execution of strategic pivots.

Strategic pivot: Pharma Direct & platform scale

Rapid Pharma Direct growth, deep manufacturer partnerships and large consumer reach (nearly 300M annual visits) shift GoodRx toward higher-growth, manufacturer‑funded programs. This structural move diversifies revenue away from low-margin transactions and can lift long-term growth and margins if execution scales.

Negative Factors

Core prescription transaction decline

A sustained decline in prescription transactions and active users undermines the company’s traditional volume-driven economics. Reduced transaction flow lowers fee income and platform leverage, making durable recovery dependent on replacing lost marketplace volume or materially higher margins elsewhere.

Unit economics reset / lower fees

Renegotiated lower partner fees trade near-term take-rate for predictability but compress per-transaction economics. Lowered unit economics can structurally reduce gross margins and long-term revenue per user unless offset by higher volumes, new higher-margin channels, or sustained manufacturer revenue growth.

2026 guidance implies contraction

Company is explicitly accepting a near-term revenue and EBITDA step-down to invest in strategic priorities. While potentially constructive long-term, this creates execution risk over the next 2–6 months: investments must scale to offset lost legacy income or the profitability trajectory could deteriorate further.

GoodRx Holdings Business Overview & Revenue Model

Company Description

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.

How the Company Makes Money

GoodRx generates revenue through several key streams. The primary source of income comes from the fees it earns when consumers use its platform to obtain discounts on prescription medications. When a user redeems a coupon at a pharmacy, GoodRx receives a transaction fee from the pharmacy or pharmacy benefit manager (PBM). Additionally, GoodRx partners with healthcare providers and telehealth services, earning revenue from telehealth consultations and prescriptions facilitated through its platform. The company also explores advertising opportunities and partnerships with pharmaceutical companies, allowing for additional income through sponsored listings and promotions. These diverse revenue streams contribute to GoodRx's overall earnings, leveraging both consumer engagement and partnerships within the healthcare ecosystem.

GoodRx Holdings Financial Statement Overview

Summary

Fundamentals show improvement with a de-risked balance sheet (material debt reduction) and consistently positive operating/free cash flow, supporting stability. Offsetting this, revenue contracted sharply in 2025 and profitability has been volatile historically, creating uncertainty around the durability of the rebound.

Income Statement

Profitability has improved meaningfully versus earlier years, with net income turning solidly positive in 2025 on very strong gross margins. However, growth is the key concern: revenue fell sharply in 2025 after modest growth in 2024, and profitability has been volatile over the period (losses in 2020–2023 before the recent rebound). The setup suggests a stronger earnings profile today, but with elevated uncertainty around the durability of top-line demand.

Balance Sheet

The balance sheet strengthened materially in 2025, with debt dropping sharply and leverage moving from relatively high levels in 2020–2024 to low debt versus equity in 2025. Equity remains sizable relative to assets, and returns on equity improved significantly in 2025 after being weak/negative in prior years. Main watch-outs are the historically higher leverage and the fact that returns have not been consistently strong year-to-year.

Cash Flow

Cash generation is consistently positive across the period, with healthy operating cash flow and positive free cash flow each year. That said, free cash flow declined in 2025 (after improvement in 2024), and in 2025 cash conversion weakened versus the prior year (operating cash flow and free cash flow were a smaller share of net income than in 2024). Overall, cash flow quality is good, but the recent step-down in cash conversion and free cash flow growth is a near-term risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	796.85M	792.32M	750.26M	766.55M	745.42M
Gross Profit	739.26M	744.11M	683.34M	701.48M	698.71M
EBITDA	184.36M	153.92M	108.82M	65.19M	48.00M
Net Income	82.64M	16.39M	-8.87M	-32.83M	-25.25M
Balance Sheet
Total Assets	1.40B	1.39B	1.59B	1.60B	1.61B
Cash, Cash Equivalents and Short-Term Investments	261.82M	448.35M	672.30M	757.16M	941.11M
Total Debt	59.54M	543.39M	711.07M	717.02M	702.33M
Total Liabilities	787.80M	663.41M	826.84M	789.80M	775.95M
Stockholders Equity	616.26M	724.66M	761.96M	814.83M	831.68M
Cash Flow
Free Cash Flow	76.83M	113.55M	82.53M	91.57M	144.32M
Operating Cash Flow	135.02M	183.89M	138.29M	146.78M	178.78M
Investing Cash Flow	-88.19M	-70.35M	-55.77M	-210.50M	-178.73M
Financing Cash Flow	-221.64M	-337.50M	-167.40M	-120.23M	-30.53M

GoodRx Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 2.28, below the 50-day MA of 2.54, and below the 200-day MA of 3.65, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 36.89 is Neutral, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDRX.

GoodRx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GDRX	60 Neutral	$634.74M	22.21	4.54%	―	1.30%	―
PHR	60 Neutral	$743.34M	-128.30	-1.87%	―	14.33%	93.62%
CCLD	58 Neutral	$103.87M	60.20	21.49%	―	2.97%	―
OMDA	56 Neutral	$711.11M	-26.41	―	―	50.51%	50.92%
TDOC	53 Neutral	$938.37M	-4.61	-13.93%	―	-2.37%	77.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMWL	46 Neutral	$94.35M	-0.96	-35.42%	―	4.33%	50.50%

GoodRx Holdings Corporate Events

GoodRx Approves Retention Bonuses for CEO and CFO

On December 9, 2025, GoodRx Holdings‘ Board of Directors approved retention bonus agreements for CEO Wendy Barnes and CFO Chris McGinnis, offering them cash bonuses of $2 million and $1 million, respectively. These bonuses are contingent upon their continued employment, with repayment conditions if they leave the company under certain circumstances before the end of 2027. The agreements exclude them from participating in the company’s 2025 executive bonus plan or other cash incentive programs for that year.

The most recent analyst rating on (GDRX) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.